July 8, 2012

Randomized Trial of Short-Course High-Dose Erythropoietin in Donation After Cardiac Death Kidney Transplant Recipients

.   .   

Donation after cardiac death (DCD) donors have become an important source of organs, but the rates of delayed graft function (DGF) remains high. Erythropoietin may protect against schema-reperfusion injury. In this randomized controlled trial, erythropoietin or placebo was given to recipients of DCD kidneys. There was no difference in DGF rates, acute rejection, or renal function by one year post-transplant. However, there was an increased incidence of thrombotic events in the erythropoietin group, even up to a year post-transplant.

Related Articles:

Renal Transplantation

Comments are closed.